Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.
A total of 38 patients with 39 infections involving a variety of organ systems were treated with moxalactam. The overall cure rate was 79.5%. Most of the failures occurred in patients with severe underlying disease such as peripheral vascular disease. The cure rate for infections with Pseudomonas aeruginosa was 62.5% (10 of 16) and for nonpseudomonal infections was 91% (21 of 23). However, excluding the six infections involving organisms which were initially resistant to moxalactam, the cure rate for pseudomonal infections was 77% (10 of 13) compared with 90% (18 of 20) for nonpseudomonal infections. Two patients with gram-negative bacillary meningitis were cured, as were seven of eight with mixed aerobic-anaerobic infections. There were no serious adverse drug effects. Three patients became colonized with the enterococcus and two became colonized with Candida albicans; one other patient developed candida vaginitis. These results suggest that moxalactam will be a valuable drug in therapy of gram-negative bacillary and anaerobic infections.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009070:Moxalactam; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam